«A PHASE 3 OPEN-LABEL, RANDOMISED STUDY OF DATOPOTAMAB DERUXTECAN (DATO-DXD) WITH or WITHOUT DURVALUMAB VERSUS INVESTIGATOR’S CHOICE OF THERAPY IN PATIENTS WITH STAGE I-III TRIPLE-NEGATIVE BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN THE BREAST AND/OR AXILLARY LYMPH NODES AT SURGICAL RESECTION FOLLOWING NEOADJUVANT SYSTEMIC THERAPY (TROPION-BREAST03) »